Exicure, Inc.(XCUR)

Biotechnology · Redwood City, CA

$1.11+0.04 (+3.74%)

Delayed quote: Oct 6, 2026, 2:30 PM EDT

EV/EBITDA Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBITDA ratio is N/A as of 2026-10-06T18:48:27.781Z.

Stored calculation inputs

Calculation as of: 2026-10-06T18:48:27.781Z.

Quote observation: 2026-10-06T18:30:05.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 7,075,070
Total debt · period ending 2026-06-30: 0
Cash · period ending 2026-06-30: 1,717,000
TTM operating EBITDA · period ending 2026-06-30: -6,930,000

FMP input reference: 62e543f524ee8633d6080f2a553f9cbd6b945788c6a084cb4464cef9d8d253d7

EV/Sales|P/E Ratio|EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

XCUR EV/EBITDA Ratio Metrics

EV/EBITDA RATIO

N/A

XCUR Competitors' EV/EBITDA Ratio

XCUR

Exicure, Inc.

Current

Market Cap

$7.08M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NRSN

NeuroSense Therapeutics Ltd.

vs XCUR

Market Cap

$6.95M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

KALA

KALA BIO, Inc.

vs XCUR

Market Cap

$7.02M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

MGRX

Mangoceuticals, Inc.

vs XCUR

Market Cap

$7.07M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CURX

Curanex Pharmaceuticals Inc Common Stock

vs XCUR

Market Cap

$7.01M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CODX

Co-Diagnostics, Inc.

vs XCUR

Market Cap

$6.97M

EV/EBITDA Ratio

N/A

TTM Avg

1.39x

3Y Avg

7.68x

5Y Avg

7.68x

LGVN

Longeveron Inc.

vs XCUR

Market Cap

$7.21M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

INM

InMed Pharmaceuticals Inc.

vs XCUR

Market Cap

$7.32M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

SKYE

Skye Bioscience, Inc.

vs XCUR

Market Cap

$7.29M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

BOLT

Bolt Biotherapeutics, Inc.

vs XCUR

Market Cap

$6.78M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/EBITDA RATIO	TTM	3Y	5Y
Exicure, Inc. (XCUR)	$7.08M	N/A	N/A	N/A	N/A
NeuroSense Therapeutics Ltd. (NRSN)vs ›	$6.95M	N/A	N/A	N/A	N/A
KALA BIO, Inc. (KALA)vs ›	$7.02M	N/A	N/A	N/A	N/A
Mangoceuticals, Inc. (MGRX)vs ›	$7.07M	N/A	N/A	N/A	N/A
Curanex Pharmaceuticals Inc Common Stock (CURX)vs ›	$7.01M	N/A	N/A	N/A	N/A
Co-Diagnostics, Inc. (CODX)vs ›	$6.97M	N/A	1.39x	7.68x	7.68x
Longeveron Inc. (LGVN)vs ›	$7.21M	N/A	N/A	N/A	N/A
InMed Pharmaceuticals Inc. (INM)vs ›	$7.32M	N/A	N/A	N/A	N/A
Skye Bioscience, Inc. (SKYE)vs ›	$7.29M	N/A	N/A	N/A	N/A
Bolt Biotherapeutics, Inc. (BOLT)vs ›	$6.78M	N/A	N/A	N/A	N/A

EV/EBITDA Ratio Formula & Definition

EV/EBITDA = Enterprise Value / EBITDA (TTM)

Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/Sales P/E Ratio EBITDA All Metrics